When Ally Bain, a teenager with Crohn's disease, was denied access to a restroom in a Chicago clothing store (even with a
card detailing her medical condition), she had an accident. She also vowed to prevent others from having to go through such
pain and humiliation. She took her cause to the Illinois state legislature, which passed "Ally's Law," giving people with
debilitating intestinal disorders access to any business restroom.
Ally told a powerful story for an underserved population, the right people listened, and the results were substantial. Her
story garnered an even wider audience on
http://crohnsandme.com/, a Web 2.0 site developed by Heartbeat Digital and sponsored by UCB Group.
Initially launched as an unbranded site, it now highlights information on UCB's Cimzia (certolizumab pegol), a biologic that
received FDA approval in April for adults with moderate to severe Crohn's disease who have not responded to conventional therapies.
Crohn's disease is a chronic, inflammatory bowel disease that affects more than one million men and women worldwide.
A win/win situation
The marketing challenge was to deliver a 2.0 Web site,
http://crohnsandme.com/, that offered community and supplied patients with goals for living a normal life. The Web site includes videos of Ally Bain
and other Crohn's patients (and their doctors and family members) telling their stories about surviving, and even thriving,
with the condition. It also includes information on the 50-state advocacy program created by the agency to spread the word.
For the client, UCB Group, the challenge was to build an initially unbranded Web site that would yield a significant database
of highly qualified patients. The database and the Web site could then be used to communicate with patients about the company's
new treatment option. The secondary goal was to introduce UCB Group, with headquarters in Brussels, to US patients, and to
position them as a patient-centric company.
Database acquisition goals for the first year were met two months after the site's launch. Currently, the number of database
patients stands at eight times the original goal. Engagement goals also have been positive–the length of stay for unregistered
users is more than twice the industry benchmark, for registered users, it's more than four times.
In creating the site, the first step was to analyze Crohn's disease space online. Not surprisingly, it was heavily populated
with sites (both branded and unbranded) for treatments, along with national associations and patient advocacy groups. These
well-trafficked sites offered abundant, well-crafted information about the disease. Further analysis, however, showed the
average length of stay for these sites was low–below the pharma industry average of about four minutes. So although these
online options appealed to users at first, the content wasn't compelling enough to warrant sticking around. On the whole,
the stories being told were undifferentiated—not uniquely valuable to patients.
On the other hand, further searching uncovered a small Crohn's-specific UK-based Web site that bucked the trend with an impressive
average length of stay of about six minutes. It was the kind of site that would not have been on anyone's radar as a key competitor,
but it clearly warranted a deeper look.